14 results on '"Chi-yuan Hsu"'
Search Results
2. Hospitalization Trajectories and Risks of ESKD and Death in Individuals With CKD
- Author
-
Anand Srivastava, Xuan Cai, Rupal Mehta, Jungwha Lee, David I. Chu, Katherine T. Mills, Tariq Shafi, Jonathan J. Taliercio, Jesse Y. Hsu, Sarah J. Schrauben, Milda R. Saunders, Clarissa J. Diamantidis, Chi-yuan Hsu, Sushrut S. Waikar, James P. Lash, Tamara Isakova, Lawrence J. Appel, Harold I. Feldman, Alan S. Go, Jiang He, Robert G. Nelson, Mahboob Rahman, Panduranga S. Rao, Vallabh O. Shah, Raymond R. Townsend, and Mark L. Unruh
- Subjects
chronic kidney disease ,end-stage kidney disease ,hospital utilization ,hospitalization ,trajectory ,Diseases of the genitourinary system. Urology ,RC870-923 - Abstract
Introduction: Management of chronic kidney disease (CKD) entails high medical complexity and often results in high hospitalization burden. There are limited data on the associations of longitudinal hospital utilization patterns with adverse clinical outcomes in individuals with CKD. Methods: We derived cumulative all-cause hospitalization trajectory groups using latent class trajectory analysis in 3012 participants of the Chronic Renal Insufficiency Cohort (CRIC) Study who were alive and did not reach end-stage kidney disease (ESKD) within 4 years of study entry. Cox proportional hazards models tested the associations between hospitalization trajectory groups and risks of ESKD and death prior to the onset of ESKD (ESKD-censored death). Results: Within 4 years of study entry, there were 5658 hospitalizations among 3012 participants. We identified 3 distinct subgroups of individuals with CKD based on cumulative all-cause hospitalization trajectories over 4 years: low-utilizer (n = 1066), intermediate-utilizer (n = 1802), and high-utilizer (n = 144). High-utilizers represented a patient population of lower socioeconomic status who had a greater prevalence of comorbid conditions and lower kidney function compared with intermediate- and low-utilizers. After the 4-year ascertainment period to form the trajectory subgroups, there were 544 ESKD events and 437 ESKD-censored deaths during a median follow-up time of 5.1 years. Compared with low-utilizers, intermediate-utilizers and high-utilizers were at 1.49-fold (95% confidence interval [CI] 1.22–1.84) and 1.75-fold (95% CI 1.20–2.56) higher risk of ESKD in adjusted analyses, respectively. Compared with low-utilizers, intermediate-utilizers and high-utilizers were at 1.48-fold (95% CI 1.17–1.87) and 2.58-fold (95% CI 1.74–3.83) higher risk of ESKD-censored death in adjusted analyses, respectively. Conclusions: Trajectories of cumulative all-cause hospitalization identify subgroups of individuals with CKD who are at high risk of ESKD and death.
- Published
- 2021
- Full Text
- View/download PDF
3. APOL1 Long-term Kidney Transplantation Outcomes Network (APOLLO): Design and Rationale
- Author
-
Barry I. Freedman, Marva M. Moxey-Mims, Amir A. Alexander, Brad C. Astor, Kelly A. Birdwell, Donald W. Bowden, Gordon Bowen, Jonathan Bromberg, Timothy E. Craven, Darshana M. Dadhania, Jasmin Divers, Mona D. Doshi, Elling Eidbo, Alessia Fornoni, Michael D. Gautreaux, Rasheed A. Gbadegesin, Patrick O. Gee, Giselle Guerra, Chi-yuan Hsu, Ana S. Iltis, Nichole Jefferson, Bruce A. Julian, David K. Klassen, Patrick P. Koty, Carl D. Langefeld, Krista L. Lentine, Lijun Ma, Roslyn B. Mannon, Madhav C. Menon, Sumit Mohan, J. Brian Moore, Barbara Murphy, Kenneth A. Newell, Jonah Odim, Mariella Ortigosa-Goggins, Nicholette D. Palmer, Meyeon Park, Afshin Parsa, Stephen O. Pastan, Emilio D. Poggio, Nishadi Rajapakse, Amber M. Reeves-Daniel, Sylvia E. Rosas, Laurie P. Russell, Deirdre Sawinski, S. Carrie Smith, Mitzie Spainhour, Robert J. Stratta, Matthew R. Weir, David M. Reboussin, Paul L. Kimmel, and Daniel C. Brennan
- Subjects
Diseases of the genitourinary system. Urology ,RC870-923 - Abstract
Introduction: Much of the higher risk for end-stage kidney disease (ESKD) in African American individuals relates to ancestry-specific variation in the apolipoprotein L1 gene (APOL1). Relative to kidneys from European American deceased-donors, kidneys from African American deceased-donors have shorter allograft survival and African American living-kidney donors more often develop ESKD. The National Institutes of Health (NIH)–sponsored APOL1 Long-term Kidney Transplantation Outcomes Network (APOLLO) is prospectively assessing kidney allograft survival from donors with recent African ancestry based on donor and recipient APOL1 genotypes. Methods: APOLLO will evaluate outcomes from 2614 deceased kidney donor-recipient pairs, as well as additional living-kidney donor-recipient pairs and unpaired deceased-donor kidneys. Results: The United Network for Organ Sharing (UNOS), Association of Organ Procurement Organizations, American Society of Transplantation, American Society for Histocompatibility and Immunogenetics, and nearly all U.S. kidney transplant programs, organ procurement organizations (OPOs), and histocompatibility laboratories are participating in this observational study. APOLLO employs a central institutional review board (cIRB) and maintains voluntary partnerships with OPOs and histocompatibility laboratories. A Community Advisory Council composed of African American individuals with a personal or family history of kidney disease has advised the NIH Project Office and Steering Committee since inception. UNOS is providing data for outcome analyses. Conclusion: This article describes unique aspects of the protocol, design, and performance of APOLLO. Results will guide use of APOL1 genotypic data to improve the assessment of quality in deceased-donor kidneys and could increase numbers of transplanted kidneys, reduce rates of discard, and improve the safety of living-kidney donation. Keywords: African Americans, APOL1, chronic kidney disease, graft failure, kidney transplantation, outcomes
- Published
- 2020
- Full Text
- View/download PDF
4. Interventions to Improve Blood Pressure Control Among Socioeconomically Disadvantaged Patients With CKD: Kidney Awareness Registry and Education Pilot Randomized Controlled Trial
- Author
-
Delphine S. Tuot, Anna D. Rubinsky, Alexandra Velasquez, Charles E. McCulloch, Dean Schillinger, Margaret A. Handley, Chi-yuan Hsu, and Neil R. Powe
- Subjects
Diseases of the genitourinary system. Urology ,RC870-923 - Abstract
Rationale & Objective: Sustainable interventions that enhance chronic kidney disease (CKD) management are not often studied in safety-net primary care, in which populations bear a disproportionate burden of disease and experience translational gaps between research and practice. We tested the feasibility of implementing and the impact of 2 technology-enhanced interventions designed to enhance CKD care delivery. Study Design: A 2×2 randomized controlled pilot trial. Setting & Participants: Primary care provider teams (n = 6) and 137 patients with CKD aged 18 to 75 years from 2 safety-net primary care clinics, 2013 to 2015. Interventions: Primary care provider teams were randomly assigned to access a CKD registry with point-of-care notifications and quarterly feedback or a usual-care registry for 12 months. Patients within provider teams were randomly assigned to participate in a CKD self-management support program or usual care for 12 months. Outcomes: We examined recruitment, randomization, and participation in each intervention. We also examined the impact of each intervention and their combination on change in systolic blood pressure (SBP), albuminuria, and patient self-reported behavioral measures after 12 months. Results: Among potentially eligible patients identified using the electronic health record, 24% were eligible for study participation, of whom 35% (n = 137) were enrolled. Mean age was 55 years, 41% were non–English speaking, and 93% were of racial/ethnic minority. Mean baseline estimated glomerular filtration rate was 70.5 (SD = 30.3) mL/min/1.73 m2; mean baseline SBP was 131 (SD = 21.8) mm Hg. Nearly 90% of clinicians reported that the CKD registry influenced their CKD management. More than 95% of patients randomly assigned to CKD self-management support engaged regularly with the intervention. Estimated changes in SBP over 1 year were nonstatistically different in each of the 3 intervention groups compared with usual care: (usual care: 0.5 [95% CI, −5.2 to 6.3] mm Hg; CKD registry only: −5.4 [95% CI, −12.2 to 1.4] mm Hg; CKD self-management support only: −6.4 [95% CI, −13.7 to 1.0] mm Hg; and CKD registry plus CKD self-management support: −0.5 [−5.5 to 4.5] mm Hg), though differences were larger among those with baseline SBPs > 140/90 mm Hg. Decreases in albuminuria were similarly nonstatistically different in each of the intervention groups compared with usual care. No differences were observed in patient self-reported behaviors. Limitations: Single health system. Conclusions: Patient and provider interventions to improve CKD care are feasible to implement in low-income settings with promising results among those with uncontrolled blood pressure. Funding: National Institute of Diabetes and Digestive and Kidney Diseases. Trial Registration: ClinicalTrials.gov, number: NCT01530958. Index Words: Chronic kidney disease, randomized controlled trial, registry, self-management support, blood pressure, chronic care model
- Published
- 2019
- Full Text
- View/download PDF
5. Predicting Renal Recovery After Dialysis-Requiring Acute Kidney Injury
- Author
-
Benjamin J. Lee, Chi-yuan Hsu, Rishi Parikh, Charles E. McCulloch, Thida C. Tan, Kathleen D. Liu, Raymond K. Hsu, Leonid Pravoverov, Sijie Zheng, and Alan S. Go
- Subjects
Diseases of the genitourinary system. Urology ,RC870-923 - Abstract
Introduction: After dialysis-requiring acute kidney injury (AKI-D), recovery of sufficient kidney function to discontinue dialysis is an important clinical and patient-oriented outcome. Predicting the probability of recovery in individual patients is a common dilemma. Methods: This cohort study examined all adult members of Kaiser Permanente Northern California who experienced AKI-D between January 2009 and September 2015 and had predicted inpatient mortality of
- Published
- 2019
- Full Text
- View/download PDF
6. Health-Related Quality of Life, Depressive Symptoms, and Kidney Transplant Access in Advanced CKD: Findings From the Chronic Renal Insufficiency Cohort (CRIC) StudyPlain-Language Summary
- Author
-
Meera Nair Harhay, Wei Yang, Daohang Sha, Jason Roy, Boyang Chai, Michael J. Fischer, L. Lee Hamm, Peter D. Hart, Chi-yuan Hsu, Yonghong Huan, Anne M. Huml, Radhakrishna Reddy Kallem, Manjula Kurella Tamura, Anna C. Porter, Ana C. Ricardo, Anne Slaven, Sylvia E. Rosas, Raymond R. Townsend, Peter P. Reese, James P. Lash, Sanjeev Akkina, Lawrence J. Appel, MD, MPH, Harold I. Feldman, MD, MSCE, Alan S. Go, MD, Jiang He, MD, PhD, John W. Kusek, PhD, Panduranga Rao, MD, and Mahboob Rahman, MD
- Subjects
Kidney Transplant ,quality-of-life ,wait-listing ,depression ,Diseases of the genitourinary system. Urology ,RC870-923 - Abstract
Rationale & Objective: Among individuals with chronic kidney disease (CKD), poor self-reported health is associated with adverse outcomes including hospitalization and death. We sought to examine the association between health-related quality-of-life (HRQoL) and depressive symptoms in advanced CKD and subsequent access to the kidney transplant waiting list. Study Design: Prospective cohort study. Setting & Population: 1,676 Chronic Renal Insufficiency Cohort (CRIC) study participants with estimated glomerular filtration rates ≤ 30 mL/min/1.73 m2 at study entry or during follow-up. Exposures: HRQoL ascertained by 5 scales of the Kidney Disease Quality of Life-36 Survey (Physical Component Summary [PCS], Mental Component Summary, Symptoms, Burdens, and Effects), with higher scores indicating better HRQoL, and depressive symptoms ascertained using the Beck Depression Inventory. Outcomes: Time to kidney transplant wait-listing and time to pre-emptive wait-listing. Analytic Approach: Time-to-event analysis using Cox proportional hazards regression. Results: During a median follow-up of 5.1 years, 652 (39%) participants were wait-listed, of whom 304 were preemptively wait-listed. Adjusted for demographics, comorbid conditions, estimated glomerular filtration rate slope, and cognitive function, participants with the highest scores on the Burden and Effects scales, respectively, had lower rates of wait-listing than those with the lowest scores on the Burden (wait-listing adjusted hazard ratio [aHR], 0.70; 95% CI, 0.57-0.85; P
- Published
- 2020
- Full Text
- View/download PDF
7. Acute Kidney Injury Ascertainment Is Affected by the Use of First Inpatient Versus Outpatient Baseline Serum Creatinine
- Author
-
Kathleen D. Liu, Chi-yuan Hsu, Jingrong Yang, Thida C. Tan, Sijie Zheng, Juan D. Ordonez, and Alan S. Go
- Subjects
Diseases of the genitourinary system. Urology ,RC870-923 - Published
- 2018
- Full Text
- View/download PDF
8. Inflammatory Markers and Risk for Cognitive Decline in Chronic Kidney Disease: The CRIC Study
- Author
-
Manjula Kurella Tamura, Karman Tam, Eric Vittinghoff, Dominic Raj, Stephen M. Sozio, Sylvia E. Rosas, Gail Makos, Claudia Lora, Jiang He, Alan S. Go, Chi-yuan Hsu, Kristine Yaffe, Lawrence J. Appel, Harold I. Feldman, John W. Kusek, James P. Lash, Akinlolu Ojo, Mahboob Rahman, and Raymond R. Townsend
- Subjects
aging ,chronic kidney disease ,cognitive decline ,dementia ,epidemiology ,inflammation ,Diseases of the genitourinary system. Urology ,RC870-923 - Abstract
Chronic kidney disease (CKD) is associated with an increased risk of cognitive decline, but the mechanisms remain poorly defined. We sought to determine the relation between serum inflammatory markers and risk of cognitive decline among adults with CKD. Methods: We studied 757 adults aged ≥55 years with CKD participating in the Chronic Renal Insufficiency Cohort Cognitive study. We measured interleukin (IL)−1β, IL-1 receptor antagonist, IL-6, tumor necrosis factor (TNF)−α, high-sensitivity C-reactive protein (hs-CRP), and fibrinogen in baseline plasma samples. We assessed cognitive function at regular intervals in 4 domains and defined incident impairment as a follow-up score more than 1 SD poorer than the group mean. Results: The mean age of the sample was 64.3 ± 5.6 years, and the mean follow-up was 6.2 ± 2.5 years. At baseline, higher levels of each inflammatory marker were associated with poorer age-adjusted performance. In analyses adjusted for baseline cognition, demographics, comorbid conditions, and kidney function, participants in the highest tertile of hs-CRP, the highest tertile of fibrinogen, and the highest tertile of IL-1β had an increased risk of impairment in attention compared to participants in the lowest tertile of each marker. Participants in the highest versus lowest tertile of TNF-α had a lower adjusted risk of impairment in executive function. There was no association between other inflammatory markers and change in cognitive function. Discussion: Among adults with CKD, higher levels of hs-CRP, fibrinogen, and IL-1β were associated with a higher risk of impairment in attention. Higher levels of TNF-α were associated with a lower risk of impaired executive function.
- Published
- 2017
- Full Text
- View/download PDF
9. APOL1 Long-term Kidney Transplantation Outcomes Network (APOLLO): Design and Rationale
- Author
-
Jonathan S. Bromberg, Darshana Dadhania, Donald W. Bowden, Laurie P Russell, Emilio D. Poggio, Barry I. Freedman, Timothy E. Craven, Madhav C. Menon, Krista L. Lentine, Bruce A. Julian, Jasmin Divers, Roslyn B. Mannon, Sylvia E. Rosas, Afshin Parsa, Nishadi Rajapakse, Nichole Jefferson, Amber Reeves-Daniel, Alessia Fornoni, Ana S. Iltis, Giselle Guerra, Elling Eidbo, Robert J. Stratta, Chi-yuan Hsu, Lijun Ma, Mitzie Spainhour, Michael D. Gautreaux, Daniel C. Brennan, Paul L. Kimmel, Nicholette D. Palmer, Mariella Ortigosa-Goggins, Matthew R. Weir, J. Brian Moore, Sumit Mohan, Carl D. Langefeld, Meyeon Park, Stephen O. Pastan, Patrick O. Gee, Amir A. Alexander, Mona D. Doshi, David K. Klassen, S. Carrie Smith, Deirdre Sawinski, Marva Moxey-Mims, David M. Reboussin, Kelly A. Birdwell, Rasheed Gbadegesin, Brad C. Astor, Kenneth A. Newell, Patrick P. Koty, Gordon Bowen, Jonah Odim, and Barbara Murphy
- Subjects
United Network for Organ Sharing ,medicine.medical_specialty ,graft failure ,030232 urology & nephrology ,kidney transplantation ,030204 cardiovascular system & hematology ,lcsh:RC870-923 ,outcomes ,03 medical and health sciences ,0302 clinical medicine ,Clinical Research ,medicine ,Family history ,APOL1 ,Kidney transplantation ,African Americans ,urogenital system ,business.industry ,lcsh:Diseases of the genitourinary system. Urology ,medicine.disease ,Institutional review board ,3. Good health ,Histocompatibility ,Transplantation ,Nephrology ,Family medicine ,Donation ,business ,chronic kidney disease ,Kidney disease - Abstract
Introduction Much of the higher risk for end-stage kidney disease (ESKD) in African American individuals relates to ancestry-specific variation in the apolipoprotein L1 gene (APOL1). Relative to kidneys from European American deceased-donors, kidneys from African American deceased-donors have shorter allograft survival and African American living-kidney donors more often develop ESKD. The National Institutes of Health (NIH)–sponsored APOL1 Long-term Kidney Transplantation Outcomes Network (APOLLO) is prospectively assessing kidney allograft survival from donors with recent African ancestry based on donor and recipient APOL1 genotypes. Methods APOLLO will evaluate outcomes from 2614 deceased kidney donor-recipient pairs, as well as additional living-kidney donor-recipient pairs and unpaired deceased-donor kidneys. Results The United Network for Organ Sharing (UNOS), Association of Organ Procurement Organizations, American Society of Transplantation, American Society for Histocompatibility and Immunogenetics, and nearly all U.S. kidney transplant programs, organ procurement organizations (OPOs), and histocompatibility laboratories are participating in this observational study. APOLLO employs a central institutional review board (cIRB) and maintains voluntary partnerships with OPOs and histocompatibility laboratories. A Community Advisory Council composed of African American individuals with a personal or family history of kidney disease has advised the NIH Project Office and Steering Committee since inception. UNOS is providing data for outcome analyses. Conclusion This article describes unique aspects of the protocol, design, and performance of APOLLO. Results will guide use of APOL1 genotypic data to improve the assessment of quality in deceased-donor kidneys and could increase numbers of transplanted kidneys, reduce rates of discard, and improve the safety of living-kidney donation., Graphical abstract
- Published
- 2019
10. Evans M, Grams ME, Sang Y, et al., for the Chronic Kidney Disease Prognosis Consortium. Risk factors for prognosis in patients with severely decreased GFR. Kidney Int Rep. 2018;3:625–637
- Author
-
Brad Astor, Lawrence J. Appel, Adeera Levin, Ognjenka Djurdjev, Mila Tang, Sankar D. Navaneethan, Stacey E. Jolly, Jesse D. Schold, Joseph V. Nally, David C. Wheeler, Jonathan Emberson, John Townend, Martin Landray, Harold I. Feldman, Chi-yuan Hsu, James P. Lash, Philip A. Kalra, James P. Ritchie, Raman Maharajan, Helen Alderson, Beverly Lane, Kai-Uwe Eckardt, Markus P. Schneider, Anna Köttgen, Florian Kronenberg, Barbara Bärthlein, Alex R. Chang, Jamie A. Green, H. Lester Kirchner, Kevin Ho, Angharad Marks, Corri Black, Gordon J. Prescott, Nick Fluck, Masaaki Nakayama, Mariko Miyazaki, Tae Yamamoto, Gen Yamada, Angela Yee-Moon Wang, Sharon Cheung, Sharon Wong, Jessie Chu, Henry Wu, Varda Shalev, Gabriel Chodick, Peter J. Blankestijn, Jack F.M. Wetzels, Arjan D. van Zuilen, Jan A. van den Brand, Andrew S. Levey, Lesley A. Inker, Mark J. Sarnak, Hocine Tighiouart, Haitao Zhang, Benedicte Stengel, Pablo G. Rios, Nelson Mazzuchi, Liliana Gadola, Verónica Lamadrid, Laura Sola, John F. Collins, C. Raina Elley, Timothy Kenealy, Olivier Moranne, Cecile Couchoud, Cecile Vigneau, Nigel J. Brunskill, Rupert W. Major, David Shepherd, James F. Medcalf, Csaba P. Kovesdy, Kamyar Kalantar-Zadeh, Miklos Z. Molnar, Keiichi Sumida, Praveen K. Potukuchi, Hiddo J.L. Heerspink, Dick de Zeeuw, Barry Brenner, Juan Jesus Carrero, Peter Barany, Abdul Rashid Qureshi, Carl-Gustaf Elinder, Frank L.J. Visseren, Yolanda van der Graaf, Marie Evans, Maria Stendahl, Staffan Schön, Mårten Segelmark, Karl-Göran Prütz, David M. Naimark, Navdeep Tangri, Patrick B. Mark, Jamie P. Traynor, Colin C. Geddes, Peter C. Thomson, Josef Coresh, Ron T. Gansevoort, Morgan E. Grams, Kunihiro Matsushita, Mark Woodward, Luxia Zhang, Shoshana H. Ballew, Jingsha Chen, Lucia Kwak, Yingying Sang, Aditya Surapaneni, Brenda R. Hemmelgarn, Wolfgang C. Winkelmayer, John Davis, Danielle Green, Michael Cheung, Tanya Green, and Melissa McMahan
- Subjects
business.industry ,Arterial disease ,Angiotensin ii antagonist ,medicine.disease ,Treatment efficacy ,Optimal management ,Nephrology ,Cohort ,Medicine ,In patient ,business ,Corrigendum ,Humanities ,Cohort study ,Kidney disease - Abstract
The Chronic Kidney Disease (CKD) Prognosis Consortium is a collaborative author of the above-mentioned article. The CKD Prognosis Consortium investigators/collaborators are as follows: • African American Study of Kidney Disease and Hypertension (AASK): Brad Astor, Lawrence J. Appel; British Columbia CKD Study (BC CKD): Adeera Levin, Ognjenka Djurdjev; Canadian Study of Prediction of Death, Dialysis and Interim Cardiovascular Events (CanPREDDICT): Adeera Levin, Mila Tang, Ognjenka Djurdjev; Cleveland Clinic CKD Registry Study (CCF): Sankar D. Navaneethan, Stacey E. Jolly, Jesse D. Schold, Joseph V. Nally Jr; Chronic Renal Impairment in Birmingham (CRIB): David C. Wheeler, Jonathan Emberson, John Townend, Martin Landray; Chronic Renal Insufficiency Cohort Study (CRIC): Harold I. Feldman, Chi-yuan Hsu, James P. Lash, Lawrence J. Appel; Chronic Renal Insufficiency Standards Implementation Study (CRISIS): Philip A. Kalra, James P. Ritchie, Raman Maharajan, Helen Alderson, Beverly Lane; German Chronic Kidney Disease Study (GCKD): Kai-Uwe Eckardt, Markus P. Schneider, Anna Kottgen, Florian Kronenberg, Barbara Barthlein; Geisinger Health System: Alex R. Chang, Jamie A. Green, H. Lester Kirchner, Kevin Ho; Grampian Laboratory Outcomes, Morbidity and Mortality Studies – 2 (GLOMMS2): Angharad Marks, Corri Black, Gordon J. Prescott, Nick Fluck; Gonryo Study: Masaaki Nakayama, Mariko Miyazaki, Tae Yamamoto, Gen Yamada; Hong Kong CKD Studies: Angela Yee-Moon Wang, Sharon Cheung, Sharon Wong, Jessie Chu, Henry Wu; Maccabi Health System: Varda Shalev, Gabriel Chodick; Multifactorial Approach and Superior Treatment Efficacy in Renal Patients with the Aid of a Nurse Practitioner (MASTERPLAN): Peter J. Blankestijn, Jack F.M. Wetzels, Arjan D. van Zuilen, Jan A. van den Brand; Modification of Diet in Renal Disease Study (MDRD): Andrew S. Levey, Lesley A. Inker, Mark J. Sarnak, Hocine Tighiouart; Nanjing CKD Network Cohort Study (Nanjing CKD): Haitao Zhang; NephroTest Study: Benedicte Stengel; National Renal Healthcare Program – Uruguay (NRHP-URU): Pablo G. Rios, Nelson Mazzuchi, Liliana Gadola, Veronica Lamadrid, Laura Sola; New Zealand Diabetes Cohort Study (NZDCS): John F. Collins, C. Raina Elley, Timothy Kenealy; Parcours de Soins des Personnes Agees (PSPA): Olivier Moranne, Cecile Couchoud, Cecile Vigneau; Primary-Secondary Care Partnership to Prevent Adverse Outcomes in Chronic Kidney Disease (PSP CKD): Nigel J. Brunskill, Rupert W. Major, David Shepherd, James F. Medcalf; Racial and Cardiovascular Risk Anomalies in CKD Cohort (RCAV): Csaba P. Kovesdy, Kamyar Kalantar-Zadeh, Miklos Z. Molnar, Keiichi Sumida, Praveen K. Potukuchi; Reduction of Endpoints in Non-insulin Dependent Diabetes Mellitus with the Angiotensin II Antagonist Losartan (RENAAL): Hiddo J.L. Heerspink, Dick de Zeeuw, Barry Brenner; Stockholm CREAtinine Measurements Cohort (SCREAM): Juan Jesus Carrero, Peter Barany, Abdul Rashid Qureshi, Carl-Gustaf Elinder; Second Manifestations of ARTerial Disease Study (SMART): Frank L.J. Visseren, Yolanda van der Graaf; Swedish Renal Registry CKD Cohort (SRR CKD): Marie Evans, Maria Stendahl, Staffan Schon, Marten Segelmark, Karl-Goran Prutz; Sunnybrook Cohort: David M. Naimark, Navdeep Tangri; West of Scotland CKD Study: Patrick B. Mark, Jamie P. Traynor, Colin C. Geddes, Peter C. Thomson.• CKD Prognosis Consortium Steering Committee: Alex R. Chang, Josef Coresh (Chair), Ron T. Gansevoort, Morgan E. Grams, Anna Kottgen, Andrew S. Levey, Kunihiro Matsushita, Mark Woodward, Luxia Zhang.• CKD Prognosis Consortium Data Coordinating Center: Shoshana H. Ballew (Assistant Project Director), Jingsha Chen (Programmer), Josef Coresh (Principal Investigator), Morgan E. Grams (Director of Nephrology Initiatives), Lucia Kwak (Programmer), Kunihiro Matsushita (Director), Yingying Sang (Lead Programmer), Aditya Surapaneni (Programmer), Mark Woodward (Senior Statistician).• Kidney Disease Improving Global Outcomes (KDIGO) Controversies Conference on Prognosis and Optimal Management of Patients with Advanced CKD: Kai-Uwe Eckardt (Conference Co-Chair), Brenda R. Hemmelgarn (Conference Co-Chair), David C. Wheeler (KDIGO Co-Chair), Wolfgang C. Winkelmayer (KDIGO Co-Chair), John Davis (CEO), Danielle Green (Managing Director), Michael Cheung (Chief Scientific Officer), Tanya Green (Communications Director), Melissa McMahan (Programs Director).
- Published
- 2018
11. Contributors
- Author
-
Andrew Advani, Michael Allon, Amanda Hyre Anderson, Gerald B. Appel, Suheir Assady, Anthony Atala, Colin Baigent, Sevcan A. Bakkaloglu, Gina-Marie Barletta, Gavin J. Becker, Rinaldo Bellomo, Jeffrey S. Berns, Vivek Bhalla, Jürg Biber, Daniel G. Bichet, René J.M. Bindels, Melissa B. Bleicher, Jon D. Blumenfeld, Alain Bonnardeaux, Joseph V. Bonventre, William D. Boswell, Donald W. Bowden, Barry M. Brenner, Matthew D. Breyer, Richard M. Breyer, Dennis Brown, Carlo Brugnara, Timothy E. Bunchman, David A. Bushinsky, Stéphan Busque, Juan Jesús Carrero, Daniel Cattran, James C. Chan, Anil Chandraker, Ingrid J. Chang, Devasmita Choudhury, Fredric L. Coe, John F. Collins, H. Terence Cook, Ricardo Correa-Rotter, Shawn E. Cowper, Paolo Cravedi, Alfonso M. Cueto-Manzano, Vivette D. D’Agati, Mogomat Razeen Davids, Scott E. Delacroix, Bradley M. Denker, Thomas A. Depner, Thomas D. DuBose, Kai-Uwe Eckardt, Mohamed T. Eldehni, David H. Ellison, Michael Emmett, Ronald J. Falk, Harold I. Feldman, Robert A. Fenton, Andrew Z. Fenves, Kevin W. Finkel, Paola Fioretto, Damian G. Fogarty, John R. Foringer, Denis Fouque, Barry I. Freedman, Jørgen Frøkiaer, John W. Funder, David S. Game, Richard E. Gilbert, Jared J. Grantham, Mitchell L. Halperin, Matthew Hand, Donna S. Hanes, David C.H. Harris, Raymond C. Harris, Richard Haynes, Joost G.J. Hoenderop, Ewout J. Hoorn, Thomas H. Hostetter, Chi-yuan Hsu, Shih Hua-Lin, Hassan N. Ibrahim, Ajay K. Israni, Jossein Jadvar, J. Charles Jennette, Eric Jonasch, Kamel S. Kamel, S. Ananth Karumanchi, Bertram L. Kasiske, John A. Kellum, Carolyn J. Kelly, Ramesh Khanna, David K. Klassen, Christine J. Ko, Harbir Singh Kohli, Curtis K. Kost, L. Spencer Krane, Jordan Kreidberg, Tae-Hwan Kwon, Amit Lahoti, Martin J. Landray, John H. Laragh, Harold E. Layton, Moshe Levi, Bengt Lindholm, Frank Liu, Valerie A. Luyckx, David A. Maddox, Yoshiro Maezawa, Arthur J. Matas, Michael Mauer, Ivan D. Maya, Sharon E. Maynard, Alicia A. McDonough, Christopher W. McIntyre, Timothy W. Meyer, William E. Mitch, Orson W. Moe, Sharon M. Moe, Bruce A. Molitoris, Alvin H. Moss, David B. Mount, Karen A. Munger, Patrick H. Nachman, Saraladevi Naicker, Søren Nielsen, Eric G. Neilson, Lindsay E. Nicolle, Daniel B. Ornt, Manuel Palacín, Paul M. Palevsky, Suzanne L. Palmer, Hans-Henrik Parving, Jaakko Patrakka, David Pearce, Roberto Pecoits-Filho, Carmen A. Peralta, Norberto Perico, Neil R. Powe, Kearkiat Praditpornsilpa, Jeppe Prætorius, Susan E. Quaggin, L. Darryl Quarles, Jai Radhakrishnan, Rawi Ramadan, Piero Reggenenti, Heather N. Reich, Andrea Remuzzi, Giuseppe Remuzzi, Stephen S. Rich, Miguel C. Riella, Eberhard Ritz, Claudio Ronco, Norman D. Rosenblum, Peter Rossing, Dvora Rubinger, Robert K. Rude, Ernesto Sabath, Venkata Sabbisetti, Vinay Sakhuja, Alan D. Salama, Jeff M. Sands, Fernando Santos, Mohamed H. Sayegh, John D. Scandling, Franz Schaefer, Jon I. Scheinman, John C. Schwartz, Asif A. Sharfuddin, Susan Shaw, Visith Sitprija, Karl L. Skorecki, Itzchak N. Slotki, James P. Smith, Miroslaw J. Smogorzewski, Stuart M. Sprague, Peter Stenvinkel, John B. Stokes, Maarten W. Taal, Manjula Kurella Tamura, Jane C. Tan, Stephen C. Textor, Ravi Thadhani, Scott C. Thomson, Vincente E. Torres, Karl Tryggvason, Meryem Tuncel, Kriang Tungsanga, Joseph G. Verbalis, Jill W. Verlander, Shoyab Wadee, I. David Weiner, Matthew R. Weir, Steven D. Weisbord, David C. Wheeler, Christopher S. Wilcox, Christopher G. Wood, Stephen H. Wright, Jane Y. Yeun, Alan S.L. Yu, Kambiz Zandi-Nejad, and Mark L. Zeidel
- Published
- 2012
12. Epidemiology of Kidney Disease
- Author
-
Chi-yuan Hsu
- Subjects
medicine.medical_specialty ,business.industry ,Internal medicine ,Epidemiology ,medicine ,medicine.disease ,business ,Kidney disease - Published
- 2012
13. Clinical Evaluation of Kidney Function
- Author
-
Chi-yuan Hsu
- Subjects
medicine.medical_specialty ,business.industry ,Urology ,Medicine ,Renal function ,business ,Clinical evaluation - Published
- 2009
14. Contributors
- Author
-
Sharon Adler, Horacio J. Adrogué, Nidhi Aggarwal, Michael Allon, Sharon Anderson, Sharon Phillips Andreoli, Gerald B. Appel, Vicente Arroyo, Phyllis August, George L. Bakris, James E. Balow, Srinivasan Beddhu, Jeffrey S. Berns, Joseph V. Bonventre, Larissa Braga, Josephine P. Briggs, Maria Luiza Caramori, Daniel C. Cattran, Arlene B. Chapman, Glenn M. Chertow, Alfred K. Cheung, Kerry C. Cho, Thomas M. Coffman, Peter J. Conlon, Jeffrey J. Connaire, Gary Curhan, Paula Dennen, Thomas D. DuBose, David H. Ellison, Michael Emmett, Ronald J. Falk, Javier Fernández, Catherine M. Goeddeke-Merickel, D. Jordi Goldstein-Fuchs, Arthur Greenberg, Martin C. Gregory, Antonio Guasch, Lakshman Gunaratnam, William L. Henrich, Friedhelm Hildebrandt, Ronald J. Hogg, Jean L. Holley, Chi-yuan Hsu, Alastair J. Hutchison, A. David Jayne, J. Charles Jennette, Wladimiro Jiménez, Bertram L. Kasiske, Nitin Khosla, Paul E. Klotman, Eugene C. Kovalik, Jean-Paul Kovalik, Michelle Whittier Krause, Wilhelm Kriz, Andrew S. Levey, Fang-Ying Lin, Stuart Linas, Nicolaos E. Madias, Roslyn B. Mannon, Diego R. Martin, Gary R. MatzkePharmD, Michael Maver, Rory McQuillan, Ankit N. Mehta, Catherine M. Meyers, Alain Meyrier, Sharon M. Moe, Marianne Monahan, Narayana S. Murali, Cynthia C. Nast, Karl A. Nath, Lindsay E. Nicolle, John F. O'Toole, Biff F. Palmer, Roberto Pisoni, Tiina Podymow, Charles D. Pusey, L. Darryl Quarles, Maya K. Rao, Giuseppe Remuzzi, Eberhard Ritz, Akber Saifullah, Alan D. Salama, Paul W. Sanders, Mark J. Sarnak, Steven J. Scheinman, Arrigo Schieppati, Jürgen B. Schnermann, Richard C. Semelka, Lesley A. Stevens, Nicholas Stoycheff, Harold M. Szerlip, Nadine D. Tanenbaum, Howard Trachtman, Joseph G. Verbalis, Anand Vardhan, Daniel E. Weiner, Christopher S. Wilcox, Jay B. Wish, Christina M. Wyatt, and Fuad N. Ziyadeh
- Published
- 2009
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.